Expression of glypican 3 in ovarian and extragonadal germ cell tumors

Debra L. Zynger, Michael J. Everton, Nikolay D. Dimov, Pauline M. Chou, Ximing J. Yang

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


Germ cell tumors (GCTs), rare malignancies that occur in a wide range of locations and display variable histologic patterns, may pose diagnostic challenges. Glypican 3 (GPC3), a membrane-bound heparan sulfate proteoglycan, has been shown to be a novel diagnostic marker in testicular GCT. However, GPC3 expression in ovarian and extragonadal GCT has not been reported. We evaluated GPC3 immunoreactivity in GCTs from 63 patients (57 children and 6 adults), including 14 ovarian and 20 extragonadal primary GCTs and 8 metastases along with 21 primary testicular GCTs for comparison. All 33 yolk sac tumors (YSTs) and both choriocarcinomas were immunoreactive for GPC3. In contrast, a minority of immature (4/10) and mature (4/35) teratomas were positive. No positivity was seen in 6 embryonal carcinomas or 5 germinomas. GPC3 is differentially expressed in ovarian and extragonadal GCTs, with expression predominantly observed in YSTs and choriocarcinoma.

Original languageEnglish (US)
Pages (from-to)224-230
Number of pages7
JournalAmerican journal of clinical pathology
Issue number2
StatePublished - Aug 2008


  • GPC3
  • Germ cell tumor
  • Glypican 3
  • Ovary
  • Pediatric
  • Yolk sac tumor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Expression of glypican 3 in ovarian and extragonadal germ cell tumors'. Together they form a unique fingerprint.

Cite this